Auregen Biotherapeutics SA
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Auregen Biotherapeutics SA - overview
Established
2016
Location
Zurich, -, Switzerland
Primary Industry
Biotechnology
About
Based in Switzerland, and founded in 2016, Auregen Biotherapeutics SA, operates as a provider of 3D bioprinting technology solutions that include a biotherapeutics platform. In December 2016, Gurnet Point Capital invested USD 53. 1 million in Auregen Biotherapeutics SA, through a growth capital deal. The company offers various biotechnology solutions that include an intellectual property platform used for 3D bioprinting that includes licenses from academic institutions and creates new treatment options for patients with rare congenital craniofacial disorders.
The company also provides regenerative medicine used for the treatment of patients with rare disorders.
Current Investors
Gurnet Point Capital
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy
Verticals
HealthTech
Company Stage
Growth Stage/Expansion
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.